G/TBT/N/CAN/429
21 October 2014 
(14-6063)  Page: 1/2
Committee on Technical Barriers to Trade  Original: English/French
 
  NOTIFICATION 
The following notification is being circulated in accordance with Article 10.6 
 
1. Notifying Member: CANADA 
If applicable, name of local government involved (Article 3.2 and 7.2):    
2. Agency responsible: Department of Health 
Name and address (including telephon e and fax numbers, email and website 
addresses, if available) of agency or authority designated to handle comments 
regarding the notification shall be indicated if different from above : 
Canada's Notification Authority and Enquiry Point 
Foreign Affairs, Trade and Development Canada 
Technical Barriers and Regulations Division (TIB) 111 Sussex Drive Ottawa, ON K1A 0G2 
Canada 
Telephone: (343)203-4273 Fax: (613)943-0346 
E-mail: enquirypoint@international.gc.ca  
3. Notified under Article 2.9.2 [ X ], 2.10.1 [   ], 5.6.2 [   ], 5.7.1 [   ], other:  
4. Products covered (HS or CCCN where applic able, otherwise national tariff heading. 
ICS numbers may be provided in addition, where applicable): Crystalline powder - 
alpha-phenylacetoacetonitrile (APAAN) (ICS: 71.060) 
5. Title, number of pages and langua ge(s) of the notified document: Notice to 
interested parties - Order amending Part 1 of Schedule VI to the Controlled Drugs and 
Substances Act and regulations amending the Schedule to the Precursor Control Regulations 
to add alpha-phenylacetoacetonitrile (2 pages, available in English and French) 
6. Description of content: This notice provides interested stakeholders with the opportunity 
to comment on Health Canada's intent to a dd alphaphenylacetoacetonitrile (APAAN) and its 
salts, isomers and salts of isomers to Part 1 of Schedule VI to the Controlled Drugs and 
Substances Act  (CDSA) and to the Schedule to the Precursor Control Regulations  (PCR) so 
that it can be controlled as a Class A precursor. Currently, APAAN is not listed on the schedules to the CDSA or the PCR.  
APAAN is a crystalline powder used as a precursor in the illicit manufacture of P-2-P, 
otherwise known as benzyl methyl ketone (BMK). P-2-P, which is already regulated as a Class A precursor in Canada, is used as a precursor in the illicit synthesis of amphetamines, primarily methamphetamines. 
The CDSA and its regulations provide a legislat ive framework for the control of substances 
that can alter mental processes, and the precursors to these substances. Both may produce harm to an individual or to society when diverted to an illicit market or use. The 
Act and its regulations have the dual purpose of protecting public health and maintaining 
public safety by balancing the need for access to these substances for legitimate industrial, medical or scientific purposes and mitigating th e risks of trafficking and diversion to illicit 
markets and uses. The PCR provide a licensing and permit framework authorizing licensed G/TBT/N/CAN/429 
 
- 2 - 
 
  dealers to conduct activities with Class A or B precursors as specified on their licences. For 
example, only licensed dealers authorized to en gage in activities with a specific Class A 
precursor can import, export, produce, package, sell or provide that Class A precursor. As 
APAAN itself is not currently known to be used for any legitimate industrial, medical or 
scientific purpose, it is proposed that it be lis ted on the schedule to the PCR so that it can 
be controlled like other Class A precursors, such as P-2-P. This will also ensure the control 
of activities with this substance in Canada in the future. 
7. Objective and rationale, including the nature of urgent problems where applicable: 
Protection of human health and the environment  
8. Relevant documents:  Canada Gazette , Part I, 27 September 2014, pages 2441-2442 
(available in English and French) 
9. Proposed date of adoption:   Anticipated for Spring 2015 
Proposed date of entry into force:   On the date the regulations are adopted   
10. Final date for comments: 23 December 2014 
11. Texts available from: Nati onal enquiry point [X] or address, telephone and fax 
numbers and email and website addresses, if available, of other body:  
The electronic version of the regulatory text can be downloaded at:  
http://www.gazette.gc .ca/rp-pr/p1/2014/2 014-09-27/pdf/g1-1 4839.pdf#page=4  
http://canadagazette.gc.ca/rp-pr/p1/20 14/2014-09-27/h tml/notice-avis-eng.php   
http://canadagazette.gc.ca/rp-pr/p1/20 14/2014-09-27/h tml/notice-avis-fra.php